Structural insight into EV-A71 3A protein and its interaction with a peptide inhibitor

Yahui Liu; Panjing Lv; Wei Wang; Jiahai Zhang; Xi Zhou; Yang Qiu; Kun Cai; Haoran Zhang; Yuan Fang; Yan Li

doi:10.1016/j.virs.2023.09.004

December 2023

Citation: Yahui Liu, Panjing Lv, Wei Wang, Jiahai Zhang, Xi Zhou, Yang Qiu, Kun Cai, Haoran Zhang, Yuan Fang, Yan Li. Structural insight into EV-A71 3A protein and its interaction with a peptide inhibitor .VIROLOGICA SINICA, 2023, 38(6) : 975-979. http://dx.doi.org/10.1016/j.virs.2023.09.004

Structural insight into EV-A71 3A protein and its interaction with a peptide inhibitor

Yahui Liu ^a ,
Panjing Lv ^a ,
Wei Wang ^b ,
Jiahai Zhang ^c ,
Xi Zhou ^d ,
Yang Qiu ^d ,
Kun Cai ^{e
,,} ,
Haoran Zhang ^{a
,,} ,
Yuan Fang ^{d
,,} ,
Yan Li ^{a,f
,,}

a. Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan, 430030, China;
b. Medical Subcenter of HUST Analytical & Testing Center, Huazhong University of Science and Technology, Wuhan, 430030, China;
c. MOE Key Laboratory for Membraneless Organelles and Cellular Dynamics, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230027, China;
d. State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China;
e. Institute of Health Inspection and Testing, Hubei Provincial Center for Disease Control and Prevention (Hubei CDC), Wuhan, 430079, China;
f. Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

Corresponding author: Kun Cai, ckreal@163.com
Haoran Zhang, hrzhang@outlook.com
Yuan Fang, fangyuan_125@163.com
Yan Li, yanli@hust.edu.cn
Received Date: 07 July 2023
Accepted Date: 22 September 2023
Available online: 26 September 2023

Abstract

Highlights
1. Our results disclosed a dihelical structure of Enterovirus A71 3A_1-57 protein in apo form.
2. We depicted rigid helices and a unique flexible C-terminus for apo-form 3A_1-57.
3. This study revealed a competitive binding-based molecular mechanism underlying inhibition of dimeric 3A by ER-DRI.

Electronic Supplementary Material

10.1016j.virs.2023.09.004-ESM.docx
References
1. Baggen, J., Thibaut, H.J., Strating, J.R.P.M., van Kuppeveld, F.J.M., 2018. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 16, 368–381.
2. Fang, Y., Liu, Z., Qiu, Y., Kong, J., Fu, Y., Liu, Y., Wang, C., Quan, J., Wang, Q., Xu, W., Yin, L., Cui, J., Xu, Y., Curry, S., Jiang, S., Lu, L., Zhou, X., 2021. Inhibition of viral suppressor of RNAi proteins by designer peptides protects from enteroviral infection in vivo. Immunity 54, 2231-2244.e6.
3. Gao, Q., Yuan, S., Zhang, C., Wang, Ying, Wang, Yizhuo, He, G., Zhang, S., Altmeyer, R., Zou, G., 2015. Discovery of Itraconazole with Broad-Spectrum In Vitro Antienterovirus Activity That Targets Nonstructural Protein 3A. Antimicrob. Agents Chemother. 59, 2654–2665.
4. Guan, X., Che, Y., Wei, S., Li, S., Zhao, Z., Tong, Y., Wang, L., Gong, W., Zhang, Y., Zhao, Y., Wu, Y., Wang, S., Jiang, R., Huang, J., Liu, Y., Luo, W., Liao, Y., Hu, X., Zhang, W., Dai, Y., Jiang, G., Min, G., Liu, F., You, X., Xu, X., Li, J., Li, C., Fan, S., Hang, L., Huang, Q., Li, Q., 2020. Effectiveness and Safety of an Inactivated Enterovirus 71 Vaccine in Children Aged 6–71 Months in a Phase IV Study. Clin. Infect. Dis. 71, 2421–2427.
5. Horova, V., Lyoo, H., Różycki, B., Chalupska, D., Smola, M., Humpolickova, J., Strating, J.R.P.M., Kuppeveld, F.J.M. van, Boura, E., Klima, M., 2019. Convergent evolution in the mechanisms of ACBD3 recruitment to picornavirus replication sites. PLOS Pathog. 15, e1007962.
6. Jones, E., Pillay, T.D., Liu, F., Luo, L., Bazo-Alvarez, J.C., Yuan, C., Zhao, S., Chen, Q., Li, Y., Liao, Q., Yu, H., Rogier van Doorn, H., Sabanathan, S., 2018. Outcomes following severe hand foot and mouth disease: A systematic review and meta-analysis. Eur. J. Paediatr. Neurol. 22, 763–773.
7. Koh, W.M., Badaruddin, H., La, H., Chen, M.I.-C., Cook, A.R., 2018. Severity and burden of hand, foot and mouth disease in Asia: a modelling study. BMJ Glob. Health 3, e000442.
8. Lim, H.X., Poh, C.L., 2019. Insights into innate and adaptive immune responses in vaccine development against EV-A71. Ther. Adv. Vaccines Immunother. 7, 2515135519888998.
9. Lu, J.-Y., Brewer, G., Li, M.-L., Lin, K.-Z., Huang, C.-C., Yen, L.-C., Lin, J.-Y., 2021. Secretory Carrier Membrane Protein 3 Interacts with 3A Viral Protein of Enterovirus and Participates in Viral Replication. Microbiol. Spectr. 9, e00475-21.
10. Mandary, M.B., Poh, C.L., 2018. Changes in the EV-A71 Genome through Recombination and Spontaneous Mutations: Impact on Virulence. Viruses 10, 320.
11. Mao, Q., Wang, Y., Bian, L., Xu, M., Liang, Z., 2016. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev. Vaccines 15, 599–606.
12. McMinn, P.C., 2002. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev. 26, 91–107.
13. Nasri, D., Bouslama, L., Pillet, S., Bourlet, T., Aouni, M., Pozzetto, B., 2007. Basic rationale, current methods and future directions for molecular typing of human enterovirus. Expert Rev. Mol. Diagn. 7, 419–434.
14. Nguyen, T.T., Chiu, C.-H., Lin, C.-Y., Chiu, N.-C., Chen, P.-Y., Le, T.T.V., Le, D.N., Duong, A.H., Nguyen, V.L., Huynh, T.N., Truong, H.K., Phan, T.L., Nguyen, T.T.T., Shih, S.-R., Huang, C.-G., Weng, Y.-J., Hsieh, E.-F., Chang, S., Chen, C., Tai, I.-C., Huang, L.-M., 2022. Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet 399, 1708–1717.
15. Norder, H., De Palma, A.M., Selisko, B., Costenaro, L., Papageorgiou, N., Arnan, C., Coutard, B., Lantez, V., De Lamballerie, X., Baronti, C., Solà, M., Tan, J., Neyts, J., Canard, B., Coll, M., Gorbalenya, A.E., Hilgenfeld, R., 2011. Picornavirus non-structural proteins as targets for new anti-virals with broad activity. Antiviral Res. 89, 204–218.
16. Ooi, M.H., Wong, S.C., Lewthwaite, P., Cardosa, M.J., Solomon, T., 2010. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 9, 1097–1105.
17. Qiu, Y., Xu, Y., Zhang, Y., Zhou, H., Deng, Y.-Q., Li, X.-F., Miao, M., Zhang, Q., Zhong, B., Hu, Y., Zhang, F.-C., Wu, L., Qin, C.-F., Zhou, X., 2017. Human Virus-Derived Small RNAs Can Confer Antiviral Immunity in Mammals. Immunity 46, 992-1004.e5.
18. Rattanakomol, P., Srimanote, P., Tongtawe, P., Khantisitthiporn, O., Supasorn, O., Thanongsaksrikul, J., 2022. Host neuronal PRSS3 interacts with enterovirus A71 3A protein and its role in viral replication. Sci. Rep. 12, 12846.
19. Rossi, P., Swapna, G.V.T., Huang, Y.J., Aramini, J.M., Anklin, C., Conover, K., Hamilton, K., Xiao, R., Acton, T.B., Ertekin, A., Everett, J.K., Montelione, G.T., 2010. A microscale protein NMR sample screening pipeline. J. Biomol. NMR 46, 11–22.
20. Ruan, Z., Liang, Y., Chen, Z., Yin, J., Li, C., Pan, P., Zhang, Q., Wu, J., Luo, Z., 2022. Enterovirus 71 non-structural protein 3A hijacks vacuolar protein sorting 25 to boost exosome biogenesis to facilitate viral replication. Front. Microbiol. 13, 1024899.
21. Salonen, A., Ahola, T., Kääriäinen, L., 2005. Viral RNA Replication in Association with Cellular Membranes, in: Marsh, M. (Ed.), Membrane Trafficking in Viral Replication. Springer Berlin Heidelberg, Berlin, Heidelberg, pp. 139–173.
22. Schmidt, N.J., Lennette, E.H., Ho, H.H., 1974. An Apparently New Enterovirus Isolated from Patients with Disease of the Central Nervous System. J. Infect. Dis. 129, 304–309.
23. Shen, Y., Bax, A., 2013. Protein backbone and sidechain torsion angles predicted from NMR chemical shifts using artificial neural networks. J. Biomol. NMR 56, 227–241.
24. Smola, M., Horova, V., Boura, E., Klima, M., 2020. Structural basis for hijacking of the host ACBD3 protein by bovine and porcine enteroviruses and kobuviruses. Arch. Virol. 165, 355–366.
25. Solomon, T., Lewthwaite, P., Perera, D., Cardosa, M.J., McMinn, P., Ooi, M.H., 2010. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 10, 778–790.
26. Teilum, K., Kunze, M.B.A., Erlendsson, S., Kragelund, B.B., 2017. (S)Pinning down protein interactions by NMR. Protein Sci. 26, 436–451.
27. Wang, S., Pang, Z., Fan, H., Tong, Y., 2023. Advances in anti-EV-A71 drug development research. J. Adv. Res., S2090-1232(23)00089-9
28. Xiao, X., Lei, X., Zhang, Z., Ma, Y., Qi, J., Wu, C., Xiao, Y., Li, L., He, B., Wang, J., 2017. Enterovirus 3A Facilitates Viral Replication by Promoting Phosphatidylinositol 4-Kinase IIIβ–ACBD3 Interaction. J. Virol. 91, e00791-17.
29. Yu, H., Cowling, B.J., 2019. Remaining challenges for prevention and control of hand, foot, and mouth disease. Lancet Child Adolesc. Health 3, 373–374.
30. Zhu, P., Ji, W., Li, D., Li, Z., Chen, Y., Dai, B., Han, S., Chen, S., Jin, Y., Duan, G., 2023. Current status of hand-foot-and-mouth disease. J. Biomed. Sci. 30, 15.
Proportional views